General Atlantic to Invest US$55 Million in Kalbe Genexine Biologics
General Atlantic to Invest US$55 Million in Kalbe Genexine Biologics
Capital to fuel Company s strategic growth into a leading biologics platform in the Southeast Asia region
Jakarta, Indonesia - January 27, 2021 - Kalbe Genexine Biologics ( KGBio or the Company ), a leading integrate biologics holding company focused on the in-licensing, clinical development, and manufacturing of novel biologicals and biosimilar molecules, today announced that General Atlantic, a leading global growth equity firm, will invest US$55 million in primary capital in the Company. The investment will support KGBio s ongoing clinical development and commercialization needs, asset acquisition plan, and production capacity expansion efforts.